Noninvasive Kidney Early detection of immune injury in kidney transplant patients presents a clear market need for noninvasive, affordable assays. NephroSant’s Qsant test could be positioned to transplant centers, nephrology clinics, and surgical teams as a proactive monitoring tool to reduce graft loss and improve patient outcomes.

LDT Launch Readiness With a planned commercial launch of the Qsant LDT at select sites after a recent Series A, there is an opportunity to engage reference sites, diagnostic laboratories, and hospital systems early to drive adoption, payer discussions, and real-world evidence generation.

Commercialization Leadership The appointment of a chief commercialization officer signals a focus on market access, partnerships, and go-to-market strategy. Target outreach to hospital procurement, transfusion and transplant service lines, and outpatient nephrology practices could accelerate channel development.

Strategic Partnerships Given the university startup origin and the niche in graft rejection monitoring, potential collaborations with transplant networks, ALLO or organ allocation initiatives, and CRO/academic consortia could expand study opportunities, regulatory engagement, and payer case-building.

Financing to Scale With a recent $16M Series A and a revenue trajectory of zero to under a million, there is room to position for additional funding rounds or strategic investors by highlighting scalable assay delivery, cloud-enabled data integration, and potential expansion into adjacent biomarker tests for immune injury.